Anti-V2 antibody deficiency in individuals infected with HIV-1 in Cameroon.
HIV-1
V1V2 region
V2 antibody deficiency
V2 conformational antibodies
V2 linear antibodies
Journal
Virology
ISSN: 1096-0341
Titre abrégé: Virology
Pays: United States
ID NLM: 0110674
Informations de publication
Date de publication:
03 2019
03 2019
Historique:
received:
07
11
2018
revised:
09
01
2019
accepted:
11
01
2019
pubmed:
22
1
2019
medline:
16
7
2019
entrez:
22
1
2019
Statut:
ppublish
Résumé
The results of the RV144 vaccine clinical trial showed a correlation between high level of anti-V1V2 antibodies (Abs) and a decreased risk of acquiring HIV-1 infection. This turned the focus of HIV vaccine design to the induction of elevated levels of anti-V2 Abs to increase vaccine efficacy. In plasma samples from HIV-1 infected Cameroonian individuals, we observed broad variations in levels of anti-V2 Abs, and 6 of the 79 plasma samples tested longitudinally displayed substantial deficiency of V2 Abs. Sequence analysis of the V2 region from plasma viruses and multivariate analyses of V2 characteristics showed a significant difference in several features between V2-deficient and V2-reactive plasma Abs. These results suggest that HIV vaccine immunogens containing a shorter V2 region with fewer glycosylation sites and higher electrostatic charges can be beneficial for induction of a higher level of anti-V2 Abs and thus contribute to HIV vaccine efficacy.
Identifiants
pubmed: 30665098
pii: S0042-6822(19)30011-X
doi: 10.1016/j.virol.2019.01.011
pmc: PMC6512328
mid: NIHMS1519121
pii:
doi:
Substances chimiques
AIDS Vaccines
0
HIV Antibodies
0
HIV Antigens
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
57-64Subventions
Organisme : NIAID NIH HHS
ID : P01 AI100151
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI112546
Pays : United States
Informations de copyright
Copyright © 2019 Elsevier Inc. All rights reserved.
Références
PLoS One. 2012;7(6):e39045
pubmed: 22720026
Trends Immunol. 2017 Jul;38(7):459-470
pubmed: 28539189
PLoS Pathog. 2018 Aug 28;14(8):e1007278
pubmed: 30153309
N Engl J Med. 2012 Apr 5;366(14):1275-86
pubmed: 22475592
J Virol. 2017 Mar 29;91(8):
pubmed: 28122974
Cytometry B Clin Cytom. 2007 Sep;72(5):387-96
pubmed: 17474130
Immunol Lett. 1996 Jun;51(1-2):101-5
pubmed: 8811352
PLoS One. 2010 Jan 20;5(1):e8805
pubmed: 20098712
J Virol. 1993 Aug;67(8):4932-44
pubmed: 7687306
Vaccine. 2016 May 23;34(24):2713-21
pubmed: 27102818
PLoS One. 2013;8(1):e53629
pubmed: 23349725
Sci Rep. 2017 Oct 4;7(1):12655
pubmed: 28978939
PLoS One. 2014 Feb 04;9(2):e87572
pubmed: 24504509
AIDS Res Hum Retroviruses. 2016 Apr;32(4):381-5
pubmed: 26681241
J Mol Biol. 1994 Oct 21;243(2):167-72
pubmed: 7523682
Immunity. 2013 Jan 24;38(1):176-86
pubmed: 23313589
PLoS One. 2017 Mar 13;12(3):e0173705
pubmed: 28288209
AIDS. 1997 Jan;11(1):128-30
pubmed: 9110092
PLoS One. 2014 Apr 04;9(4):e94002
pubmed: 24705879
J Virol. 2011 Jul;85(14):6986-95
pubmed: 21593147
J Immunol. 2002 Jul 1;169(1):595-605
pubmed: 12077293
Mol Immunol. 2015 Aug;66(2):364-74
pubmed: 25965315
J Virol. 1994 Jan;68(1):400-10
pubmed: 7504740
J Virol. 1994 Dec;68(12):8312-20
pubmed: 7525987
J Virol. 1993 Oct;67(10):6136-51
pubmed: 7690418
Virology. 2012 Jun 5;427(2):198-207
pubmed: 22402248
J Clin Microbiol. 2017 Sep;55(9):2785-2800
pubmed: 28659324
J Immunol. 2007 Nov 1;179(9):6343-51
pubmed: 17947712
J Virol. 2014 Apr;88(8):4100-12
pubmed: 24478429
J Virol. 2016 Nov 28;90(24):11007-11019
pubmed: 27707920
J Virol. 2006 Oct;80(19):9586-98
pubmed: 16973562